Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CHINA: SSRIs May Reduce Treatment-Associated Depression in HCV patients


Healio (11.12.2013) Aids Weekly Plus

An article in Healio presents a study on the use of selective serotonin reuptake inhibitors (SSRIs) to treat depression resulting from the use of pegylated interferon alfa-2a or -2b (Peg-IFN a-2a or a-2b) with ribavirin combination treatment for chronic hepatitis C virus (HCV) infection. Peg-IFN a-2a or a-2b with ribavirin treatment is considered a very effective HCV treatment. However, this treatment is associated with a 70-percent incidence of mild to moderate depression and a 20- to 40-percent incidence of major depression in chronic HCV patients. Researchers, including Yan-Yan Yu, MD, of the department of infectious diseases at China’s Peking University, performed a meta-analysis of six randomized, double-blind, placebo-controlled trials with 522 chronic HCV patients who had received Peg-IFN a-2a or a-2b with ribavirin. Those participants who were treated with SSRIs received escitalopram, citalopram, or paroxetine. Results showed that rates of depression and rescue therapy in patients who received SSRIs were significantly lower than rates for the control groups. Sustained virological response and treatment discontinuation did not differ significantly between groups. Patients treated with SSRIs had lower incidence of muscle and joint pain and respiratory problems, but significantly more dizziness. The researchers concluded that treatment with SSRIs can reduce depression associated with Peg-IFN a-2a or a-2b with ribavirin treatment significantly for chronic HCV patients without reducing sustained virological response. The researchers noted study limitations such as unavailable data and small sample sizes. The full report, “Can Antidepressants Prevent Pegylated Interferon-a/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?” was published online in the journal PLoS One (2013; doi: 10.1371/journal.pone.0076799).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in November 13, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.